PI-2620 (Tau PET Tracer)
Alzheimer's Disease, PSP
CommercialLicensed to Lantheus (Life Molecular Imaging)
Key Facts
Indication
Alzheimer's Disease, PSP
Phase
Commercial
Status
Licensed to Lantheus (Life Molecular Imaging)
Company
About AC Immune
Founded in 2003 and publicly listed on NASDAQ, AC Immune is a global leader in developing precision diagnostics and therapeutics for neurodegenerative diseases. Its strategy is validated by high-value partnerships with pharmaceutical giants like Takeda, Eli Lilly, and Janssen, which have generated over CHF 450 million in funding. The company is advancing a broad pipeline focused on pathological proteins such as Abeta, Tau, alpha-synuclein, and TDP-43, aiming to slow or prevent disease progression.
View full company profile